Edition:
India

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

40.75USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$40.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
56,654
52-wk High
$42.20
52-wk Low
$17.30

Chart for

About

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology... (more)

Overall

Beta: --
Market Cap(Mil.): $894.66
Shares Outstanding(Mil.): 29.19
Dividend: --
Yield (%): --

Financials

BRIEF-Intersect ENT Q4 Revenue $29.5 Million

* INTERSECT ENT REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

28 Feb 2018

BRIEF-Intersect ENT Reports Preliminary Q4 And Year 2017 Revenue

* - CO CONTINUES TO EXPECT TO LAUNCH SINUVA COMMERCIALLY IN Q2 OF 2018

08 Jan 2018

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

* ‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (http://bit.ly/2jwmJXW) Further company coverage:

17 Nov 2017

BRIEF-FDA performs pre-approval inspection of Intersect ENT's menlo park facility

* FDA performs pre-approval inspection of Intersect ENT's menlo park facility

06 Nov 2017

BRIEF-Intersect ENT Inc reports Q3 revenue $22.3 million

* Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​

03 Nov 2017

Competitors

  Price Chg
Medtronic PLC (MDT.N) $79.37 -0.65

Earnings vs. Estimates